Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 5/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893526 | 1.00 | HPGDS (0.36) | HPGDSSMN1; SMN2ALDH1A1CNR2POLB | |
| SCHEMBL15610628 | 0.84 | PDCD1LG2 (0.37) | — | |
| SCHEMBL19140336 | 0.84 | PDCD1LG2 (0.37) | — | |
| SCHEMBL748887 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1POLBGAAMAPT | |
| SCHEMBL9284282 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1POLBMAPTFPR2 | |
| SCHEMBL205860 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1POLBGAAMAPT | |
| SCHEMBL13686130 | 0.79 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1POLBMAPTFPR2 | |
| SCHEMBL21933694 | 0.78 | POLB (0.41) | HPGDSSMN1; SMN2ALDH1A1CNR2POLB | |
| SCHEMBL8194708 | 0.76 | HPGDS (0.38) | HPGDSSMN1; SMN2ALDH1A1CNR2POLB | |
| SCHEMBL1534859 | 0.76 | HPGDS (0.38) | HPGDSSMN1; SMN2ALDH1A1CNR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083490-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083490-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | HPGDS 700/4885SMN1; SMN2 4288/4885ALDH1A1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.